Production of Biologically Active Human Recombinant Insulin‐like Growth Factor‐I and Human Insulin‐like Binding Protein‐3 in Transgenic Rice for the Management of Diabetes, Obesity, Cancer and their Related Diseases
- Summary
- Diabetes mellitus is a common chronic disease affecting more than 10% of our population and will lead to devastating complications. Abnormal growth hormone/ insulin-like growth factor-I regulation contributes to the deterioration in glycaemic control in patients with insulin deficiency. Treatment with recombinant human insulin-like growth factor I (rhIGF-I) has been shown to reduce plasma glucose and insulin doses in both type 1 and type 2 diabetic patients. Recently, it has been demonstrated that co-administration of rhIGF-I with recombinant IGF Binding Protein 3 (rhIGFBP-3) can reduce the side effects without affecting the therapeutic efficacy. In addition to its high-binding activity to IGFs, IGFBP-3 has been found to negatively regulate cell proliferation and induce apoptosis in an IGF-independent manner. This may be an attractive feature in the potential development of IGFBP-3 as an anticancer agent. An efficient bioreactor platform for mass production of rhIGF-I and rhIGFBP-3 in transgenic rice has been identified. Results showed that transgenic plants can be developed as bioreactor for the synthesis of hIGF-I and hIGFBP-3 and the plant-produced recombinant proteins were biologically active.
237 non-conf abstract_hkstp Page 1 of 1
- Application No.
- 06/SCI/237 Inventors: Professor Samuel SUN, Department of Biology Professor TONG Chun Yip Peter, Department of Medicine and Therapeutics Mr. CHEUNG Chun Kai Stanley, Department of Medicine and Therapeutics Patent Status: US Patent and PCT Pending
- Country/Region
- Hong Kong
For more information, please click Here
